[
  {
    "brand_name": "Abecma",
    "inn_name": "idecabtagene vicleucel",
    "hcpc_code": "Q2055",
    "prior_authorization_required": "Yes",
    "indication": "Multiple myeloma",
    "indicated_population": "MM (RR, TCE, atleast four prior lines)",
    "label_population": "Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Abecma",
    "inn_name": "idecabtagene vicleucel",
    "hcpc_code": "Q2055",
    "prior_authorization_required": "Yes",
    "indication": "Multiple myeloma",
    "indicated_population": "MM (RR, TCE, atleast two prior lines)",
    "label_population": "Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Adakveo",
    "inn_name": "crizanlizumab",
    "hcpc_code": "J0791",
    "prior_authorization_required": "Yes",
    "indication": "Sickle-cell syndrome",
    "indicated_population": "Sickle-cell syndrome (in prevention of recurrent painful vaso-occlusive crises, in 16 years and older)",
    "label_population": "Adakveo is a selectin blocker indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Adzynma",
    "inn_name": "recombinant ADAMTS13",
    "hcpc_code": "J7171",
    "prior_authorization_required": "Yes",
    "indication": "Thrombotic Thrombocytopenic Purpura",
    "indicated_population": "TTP (congenital, prophylactic or on-demand ERT)",
    "label_population": "Adzynma is a human recombinant “A disintegrin and metalloproteinase with thrombospondin motifs 13” (rADAMTS13) indicated for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Alymsys",
    "inn_name": "bevacizumab",
    "hcpc_code": "Q5126",
    "prior_authorization_required": "Yes",
    "indication": "Cervical cancer",
    "indicated_population": "Cervical cancer (met, CT IT)",
    "label_population": "Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Alymsys",
    "inn_name": "bevacizumab",
    "hcpc_code": "Q5126",
    "prior_authorization_required": "Yes",
    "indication": "Colorectal cancer",
    "indicated_population": "CRC (met, naïve)",
    "label_population": "Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of:\n Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.  Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine?oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Alymsys",
    "inn_name": "bevacizumab",
    "hcpc_code": "Q5126",
    "prior_authorization_required": "Yes",
    "indication": "Colorectal cancer",
    "indicated_population": "CRC (met, 2nd line, in combi with CT)",
    "label_population": "Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of:\n Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.  Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine?oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Alymsys",
    "inn_name": "bevacizumab",
    "hcpc_code": "Q5126",
    "prior_authorization_required": "Yes",
    "indication": "Colorectal cancer",
    "indicated_population": "CRC (met, 2nd line)",
    "label_population": "Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of:\n Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.  Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine?oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Alymsys",
    "inn_name": "bevacizumab",
    "hcpc_code": "Q5126",
    "prior_authorization_required": "Yes",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (non-squamous, met, naïve)",
    "label_population": "Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of:\nUnresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Alymsys",
    "inn_name": "bevacizumab",
    "hcpc_code": "Q5126",
    "prior_authorization_required": "Yes",
    "indication": "Ovarian cancer",
    "indicated_population": "Ovarian, Peritoneal, Fallopian tube cancer (in combi with CT, 2nd line)",
    "label_population": "Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Alymsys",
    "inn_name": "bevacizumab",
    "hcpc_code": "Q5126",
    "prior_authorization_required": "Yes",
    "indication": "Renal cell carcinoma",
    "indicated_population": "RCC (met, naïve)",
    "label_population": "Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Alymsys",
    "inn_name": "bevacizumab",
    "hcpc_code": "Q5126",
    "prior_authorization_required": "Yes",
    "indication": "Glioblastoma",
    "indicated_population": "Glioblastoma (2nd line)",
    "label_population": "Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of recurrent glioblastoma in adults.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Amvuttra",
    "inn_name": "vutrisiran",
    "hcpc_code": "J0225",
    "prior_authorization_required": "Yes",
    "indication": "Amyloidosis",
    "indicated_population": "hATTR amyloidosis (polyneuropathy, in adults)",
    "label_population": "Amvuttra is a transthyretin-directed small interfering RNA indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Amvuttra",
    "inn_name": "vutrisiran",
    "hcpc_code": "J0225",
    "prior_authorization_required": "Yes",
    "indication": "Amyloidosis",
    "indicated_population": "Amyloidosis (with wild-type or hATTR cardiomyopathy, adults)",
    "label_population": "Amvuttra is a transthyretin-directed small interfering RNA indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Axtle",
    "inn_name": "pemetrexed",
    "hcpc_code": "C9399, J3490, J9999",
    "prior_authorization_required": "Yes",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (non-squamous, met, naive in combi with cisplatin)",
    "label_population": "Axtle is a folate analog metabolic inhibitor indicated:\n• in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.\n• as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.\n• as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Axtle",
    "inn_name": "pemetrexed",
    "hcpc_code": "C9399, J3490, J9999",
    "prior_authorization_required": "Yes",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (non-squamous, maintenance Tx, no progression post 1L pt CT)",
    "label_population": "Axtle is a folate analog metabolic inhibitor indicated:\n• in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.\n• as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.\n• as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Axtle",
    "inn_name": "pemetrexed",
    "hcpc_code": "C9399, J3490, J9999",
    "prior_authorization_required": "Yes",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (non-squamous, recurrent, met, post CT)",
    "label_population": "Axtle is a folate analog metabolic inhibitor indicated:\n• in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.\n• as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.\n• as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.",
    "clinical_criteria": "Not available",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  },
  {
    "brand_name": "Elrexfio",
    "inn_name": "elranatamab",
    "hcpc_code": "J0177",
    "prior_authorization_required": "Yes",
    "indication": "Multiple myeloma",
    "indicated_population": "MM (RR, TCE, atleast four prior lines)",
    "label_population": "Elrexfio is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.",
    "clinical_criteria": "Prescribed by or in consultation with an oncologist.\nApprove if per FDA approved labeling the patient has tried at least four systemic regimens and among the previous regimens tried, the patient has received at least one drug from each of the following classes: proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody.",
    "exclusion_criteria": "Not available",
    "links": "",
    "insurer": "Humana"
  }
]